Acetylon allies with Harvard University, Dana-Farber
Acetylon Pharmaceuticals Inc. (cancer, autoimmune diseases, and musculoskeletal disorders) has licensed exclusive rights to technology, methodology, and compounds from Harvard University and the Dana-Farber Cancer Institute related to histone deacetylase inhibitors for neurological and inflammatory diseases and cancer.
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.